GlassScriptPhysician profile
Graham Erickson
NPI 1316051154
$5,097.78
in general payments reported to CMS, 2019-2025
12 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Vision Therapy provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $3,750 · 2023: $280 · 2024: $437 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $854.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $3,895.31 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $339.29 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Tarsus Pharmaceuticals, INC. | $147.34 | 2024 | |
| Sun Pharmaceutical Industries INC. | $142.13 | 2019-2024 | |
| Apellis Pharmaceuticals, INC. | $121.24 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $112.01 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $110.62 | 2019 | |
| Glaukos Corporation | $96.86 | 2024 | Ce-Marked Kxla System |
| Oyster Point Pharma, INC. | $50.63 | 2024 | Tyrvaya |
| Dompe US, INC. | $36.26 | 2023 | Oxervate |
| Mallinckrodt Hospital Products INC. | $25.66 | 2025 | Acthar |
| Horizon Therapeutics Plc | $20.43 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Graham Erickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.